BLOOD COLLECTION TUBE MANUFACTURING BUSINESS PLAN

I. Executive Summary

Company Description

Integrity Biosystems (name conveys sample integrity) is a US-based medical device manufacturer in Indianapolis, Indiana, launching in 2026. We operate in the clinical diagnostics sector and make advanced blood collection tubes designed to improve diagnostic accuracy through superior material science. Our core products are vacuum blood collection tubes with enhanced additives and barrier technologies that protect analytes during transport. We manufacture in an FDA-registered facility with high-speed automation and ISO Class 7 cleanrooms to meet clinical quality and regulatory needs. One-liner: We build collection tools that preserve samples from draw to analysis.

We sell direct to clinical laboratories and large health systems via a direct-to-lab supply chain model, handling order fulfillment, lot-level traceability, and just-in-time delivery. Short-term goals: complete facility commissioning in Q2 2026 and win pilot contracts with three regional reference labs in 2026. Long-term goals: scale to national distribution, certify additional product lines, and reach 15% share of the specialty tube market within five years. Competitive edge: lab-focused logistics, material science that extends sample stability, and production quality controls that reduce lot failures. One-liner: We pair better tubes with predictable supply so labs get reliable results on schedule.

Problem

Clinical labs and hospital networks face frequent pre-analytical failures—blood sample contamination, premature clotting, and chemical degradation during transport—that cause diagnostic errors, delayed treatment, repeat blood draws, higher costs, and patient safety risk. Sample integrity failures create measurable clinical and operational harm.

Current solutions and supply chains leave gaps: recurring shortages of collection materials, inconsistent material quality, and limited control over sterility and contamination during transport. As a US-based medical device manufacturer launching in 2026 from Indianapolis with an FDA-registered, ISO Class 7 cleanroom facility, we address this gap by delivering high-performance blood collection tubes and a direct-to-lab supply model to reduce re-draws, cut turnaround time, and improve diagnostic reliability.

Solution

Healthcare providers face diagnostic risk from sample contamination, clotting, and degradation during transport, plus shortages caused by intermediary-heavy supply chains. Our solution supplies a comprehensive portfolio of blood collection tubes—including Serum Separator, EDTA Hematology, Lithium Heparin, Sodium Citrate, and high-precision DNA Stabilization tubes—engineered with advanced polymers and proprietary chemical additives to preserve sample integrity and reduce re-draws and delays.

All tubes are produced in an ISO Class 7 cleanroom under systems aligned to FDA Quality System Regulations, and are delivered via a direct-to-lab supply model to minimize stockouts and ensure on-time inventory for hospitals and clinical laboratories. One-liner: Reliable tubes designed to protect samples from collection to analysis. One-liner: Cleanroom manufacturing plus direct delivery for dependable supply.

Mission Statement

Our mission is to enhance diagnostic accuracy and improve patient outcomes by providing the healthcare industry with the most reliable and innovative blood collection technology. We commit to eliminating pre-analytical errors through scientific excellence, US-based precision manufacturing, and a transparent, direct-to-customer supply chain.

Key Success Factors

These are the core strengths that will drive growth and defensibility.

• Proprietary chemical-additive IP that differentiates product performance.
• Highly automated manufacturing that lowers unit cost and improves quality.
• Direct-to-lab sales model that reduces costs and builds long-term clinical relationships.
• High-growth molecular diagnostics market with high-margin DNA Stabilization Tubes.
• Experienced management plus FDA and ISO compliance creating a strong barrier to entry.

Financial Summary

Financial summary for the Executive Summary of the Blood Collection Tube Manufacturing business plan.

Financial requirements: initial capital expenditures total $3,725,000; minimum cash required $454,000 (minimum reached Jun-26). Anticipated returns include an IRR of 23.82% and a ROE of 221.37% with payback and breakeven in the first month (Jan-26).

Overall outlook: strong, rapid revenue and EBITDA growth with high projected investor returns.

Funding Requirements

We seek USD 4,344,000 to fund facility buildout, systems, IP, and a Jun-26 cash reserve; forecasts show Year 1 revenue of USD 11,220,000 rising to USD 124,200,000 by Year 5, EBITDA from USD 6,462,000 (2026) to USD 88,692,000 (2030), an IRR of 23.82%, ROE of 221.37%, and break-even in month one.